Nuveen
CAI

Nuveen’s Caris Life Sciences CAI Stock Holding History

Nuveen’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Sell
604,416
-59,162
-9% -$1.06M ﹤0.01% 1642
2026
Q1 		$11.9M Buy
663,578
+641,165
+2,861% +$14M ﹤0.01% 1450
2025
Q4 		$605K Hold
22,413
– – ﹤0.01% 2804
2025
Q3 		$678K Buy
+22,413
New +$715K ﹤0.01% 2788

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's CAI Position: Q2 2026 in Review

Nuveen reduced its Caris Life Sciences (CAI) stake by 8.9% in Q2 2026, selling an estimated $1.06M and leaving 604,416 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1642.

Nuveen first reported a position in CAI in Q3 2025 and has held it in 4 quarters since. The position peaked at $11.9M in Q1 2026. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Nuveen held 604,416 shares of Caris Life Sciences worth $10.8M as of Q2 2026.
  • Nuveen sold 59,162 Caris Life Sciences shares in Q2 2026, an estimated $1.06M.
  • Caris Life Sciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1642 holding.
  • Nuveen first reported a position in Caris Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • Nuveen's Caris Life Sciences position peaked at $11.9M in Q1 2026.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.